Business & Regulation

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

We speak with Sanofi’s Anju Bhalla about its appeal against NICE’s final draft guidance for Sarclisa.

Senate committee votes in favor of the nomination; full Senate vote will be next.

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.